Literature DB >> 25703530

Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons.

Saumil J Gandhi1, Xing Liang1, Xuanfeng Ding1, Timothy C Zhu1, Edgar Ben-Josef1, John P Plastaras1, James M Metz1, Stefan Both1, Smith Apisarnthanarax2.   

Abstract

PURPOSE: Stereotactic body radiation therapy (SBRT) for treatment of liver tumors is often limited by liver dose constraints. Protons offer potential for more liver sparing, but clinical situations in which protons may be superior to photons are not well described. We developed and validated a treatment decision model to determine whether liver tumors of certain sizes and locations are more suited for photon versus proton SBRT. METHODS AND MATERIALS: Six spherical mock tumors from 1 to 6 cm in diameter were contoured on computed tomography images of 1 patient at 4 locations: dome, caudal, left medial, and central. Photon and proton plans were generated to deliver 50 Gy in 5 fractions to each tumor and optimized to deliver equivalent target coverage and maximal liver sparing. Using these plans, we developed a hypothesis-generating model to predict the optimal modality for maximal liver sparing based on tumor size and location. We then validated this model in 10 patients with liver tumors.
RESULTS: Protons spared significantly more liver than photons for dome or central tumors ≥3 cm (dome: 134 ± 21 cm(3), P = .03; central: 108 ± 4 cm(3), P = .01). Our model correctly predicted the optimal SBRT modality for all 10 patients. For patients with dome or central tumors ≥3 cm, protons significantly increased the volume of liver spared (176 ± 21 cm(3), P = .01) and decreased the mean liver dose (8.4 vs 12.2 Gy, P = .01) while offering no significant advantage for tumors <3 cm at any location or for caudal and left medial tumors of any size.
CONCLUSIONS: When feasible, protons should be considered as the radiation modality of choice for dome and central tumors >3 cm to allow maximal liver sparing and potentially reduce radiation toxicity. Protons should also be considered for any tumor >5 cm if photon plans fail to achieve adequate coverage or exceed the mean liver threshold.
Copyright © 2015 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25703530     DOI: 10.1016/j.prro.2015.01.004

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  20 in total

1.  The evolving evidence for the efficacy and safety of charged particle therapy for hepatocellular carcinoma-a commentary.

Authors:  Jillian Gunther; Sunil Krishnan
Journal:  Ann Transl Med       Date:  2015-12

Review 2.  Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives.

Authors:  Gyu Sang Yoo; Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 3.  Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience.

Authors:  Masashi Mizumoto; Yoshiko Oshiro; Toshiyuki Okumura; Nobuyoshi Fukumitsu; Haruko Numajiri; Kayoko Ohnishi; Teruhito Aihara; Hitoshi Ishikawa; Koji Tsuboi; Hideyuki Sakurai
Journal:  Int J Part Ther       Date:  2016-03-24

4.  Indications of IMRT, PRT and CIRT for HCC from comparisons of dosimetry and normal tissue complication possibility.

Authors:  Jiayao Sun; Zheng Wang; Yinxiangzi Sheng; Xue Ming; Guo-Liang Jiang; Weiwei Wang
Journal:  Strahlenther Onkol       Date:  2021-10-07       Impact factor: 3.621

Review 5.  Proton Therapy in the Management of Hepatocellular Carcinoma.

Authors:  Jana M Kobeissi; Lara Hilal; Charles B Simone; Haibo Lin; Christopher H Crane; Carla Hajj
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

6.  Dosimetric Comparison of Plans for Photon- or Proton-Beam Based Radiosurgery of Liver Metastases.

Authors:  Gracinda Mondlane; Michael Gubanski; Pehr A Lind; Thomas Henry; Ana Ureba; Albert Siegbahn
Journal:  Int J Part Ther       Date:  2016-12-30

7.  Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation.

Authors:  Shaakir Hasan; Stephen Abel; Vivek Verma; Patrick Webster; W Tristam Arscott; Rodney E Wegner; Alexander Kirichenko; Charles B Simone
Journal:  J Gastrointest Oncol       Date:  2019-10

8.  Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis.

Authors:  Jen-Yu Cheng; Chieh-Min Liu; Yu-Ming Wang; Hsuan-Chih Hsu; Eng-Yen Huang; Tzu-Ting Huang; Ching-Hsin Lee; Sheng-Ping Hung; Bing-Shen Huang
Journal:  Radiat Oncol       Date:  2020-06-30       Impact factor: 3.481

Review 9.  Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies.

Authors:  Stephanie K Schaub; Pehr E Hartvigson; Michael I Lock; Morten Høyer; Thomas B Brunner; Higinia R Cardenes; Laura A Dawson; Edward Y Kim; Nina A Mayr; Simon S Lo; Smith Apisarnthanarax
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

10.  Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma.

Authors:  Tae Hyun Kim; Joong-Won Park; Bo Hyun Kim; Eun Sang Oh; Sang Hee Youn; Sung Ho Moon; Sang Soo Kim; Sang Myung Woo; Young-Hwan Koh; Woo Jin Lee; Dae Yong Kim
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.